Respiratory Infections

A new study highlights the potential predictive power of genome sequencing.

Mike Ison, MD, MS, discusses the key takeaways from the CAPSTONE-2 phase 3 trial evaluating baloxavir marboxil for the treatment of patients with influenza.

The phase 3 CAPSTONE-2 trial shows treatment with baloxavir marboxil significantly reduced the time to improvement of flu symptoms compared with placebo.

The clinical characteristics and outcomes of Pneumocystis jirovecii pneumonia differ in immunocompromised patients with and without HIV.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

From August 2014 to September 2018, the CDC received information on a total of 386 confirmed US cases of a polio-like illness occurring mostly among children.

As knowledge and awareness of rising antimicrobial resistance increase, clinicians must continue to adopt strategies for improving antibiotic use.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

An eVLP cytomegalovirus (CMV) vaccine was found to be safe and immunogenic at very low doses in healthy seronegative adults.

Jason Pogue, PharmD, BCPS-AQID, discusses the need for real-world data to support Ceftolozane/tazobactam and shares the findings of his comparative study on using the regimen to treat MDR/XDR Pseudomonas aeruginosa.

A new report on influenza vaccination rates among US health care workers finds that employer requirements help keep vaccination rates of health care workers higher than that of the general public.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Over one-third of patients with invasive aspergillosis lacked a documented immunosuppressive condition.

Telemedicine encounters in which antibiotics were prescribed for respiratory tract infections were only slightly shorter than those in which non-antibiotics, or nothing at all, were prescribed.

The results of a new study suggest the approach can help stratify patients with the disease.

Despite current recommendations, Tdap vaccine coverage in pregnant women remains suboptimal.

While conducting passive surveillance of triazole-resistant Aspergillus fumigatus cases, the CDC observed some cases occurred in patients who had never taken the antifungal medication.

Mindy Smith, BSPharm, RPh, provides tips for recommending the flu shot to patients who are more likely to get the flu.

The US Food and Drug Administration has approved Arikayce for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a limited population of patients who do not respond to conventional treatment.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

Contamination is a common aspect of nasal saline irrigations.

Scientists sought to figure out whether rapid diagnostic tests could be used to determine the susceptibility of P aeruginosa to 2 new therapies. The answer was yes, but with caveats.

What you should know before you travel this winter season.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Investigators have discovered a genetic mutation that increases the burden of Aspergillus fumigatus and can lead to complications for patients with asthma.

An examination of 17 years of data reveals that children who received the combination acellular vaccine Tdap were vulnerable to pertussis much earlier than expected. Researchers are hopeful that new vaccines will extend protection against the disease.

In August 2017, the FDA granted an NDA for a single-use of delamanid for a case of extensively drug-resistant tuberculosis.

The NIAID is sponsoring a phase 1 clinical trial to assess if a nasal influenza vaccine candidate used in combination with a licensed vaccine can enhance immune responses against influenza in children and teens.

Adding reminders to electronic health records shows promise at improving influenza vaccination rates, according to results of JAMA Open Network study.

The possibility of a new antiviral class administered as a single oral dose that is well tolerated will be a welcome addition to the treatment armamentarium for #influenza. However, its use should be limited to carefully selected individuals.